Evidence map›Paper›PMID 37298893›Full record

ReviewMolecules (Basel, Switzerland)2023

Nitric Oxide Synthases in Rheumatoid Arthritis.

Jia-Bao Huang, Zhi-Ru Chen, Shu-Long Yang, Fen-Fang Hong

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Bioconversion of Geniposide fromFoods (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Effects and molecular mechanisms ofFrontiers in pharmacology · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Anti-rheumatic property and physiological safety of KMU-11342 in in vitro and in vivo models.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jia-Bao HuangExperimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China.
Zhi-Ru ChenExperimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China.
Shu-Long YangSchool of Basic Medical Sciences, Fuzhou Medical College of Nanchang University, Fuzhou 344000, China.
Fen-Fang HongExperimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China.ORCID 0000-0001-6440-1311
Nanchang University · CN

Funding

Educational Commission of Jiangxi Province of China GJJ218104Jiangxi Provincial Natural Science Foundation of China 20212BAB206092National Natural Science Foundation of China 82060661, 81660751, 81660151Teaching reform research project of Jiangxi Province of China JXJG-22-130-1
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an autoimmune disease characterized by severe joint damage and disability. However, the specific mechanism of RA has not been thoroughly clarified over the past decade. Nitric oxide (NO), a kind of gas messenger molecule with many molecular targets, is demonstrated to have significant roles in histopathology and homeostasis. Three nitric oxide synthases (NOS) are related to producing NO and regulating the generation of NO. Based on the latest studies, NOS/NO signaling pathways play a key role in the pathogenesis of RA. Overproduction of NO can induce the generation and release of inflammatory cytokines and act as free radical gas to accumulate and trigger oxidative stress, which can involve in the pathogenesis of RA. Therefore, targeting NOS and its upstream and downstream signaling pathways may be an effective approach to managing RA. This review clearly summarizes the NOS/NO signaling pathway, the pathological changes of RA, the involvement of NOS/NO in RA pathogenesis and the conventional and novel drugs based on NOS/NO signaling pathways that are still in clinical trials and have good therapeutic potential in recent years, with an aim to provide a theoretical basis for further exploration of the role of NOS/NO in the pathogenesis, prevention and treatment of RA.

Indexed as

Arthritis, RheumatoidNitric OxideFree RadicalsHumansNitric Oxide SynthaseOxidative StressFree RadicalsNitric OxideNitric Oxide Synthasedisease-modifying antirheumatic drugsinflammatory cytokinesnitric oxidenitric oxide synthasesrheumatoid arthritis

Identifiers

PMID37298893
PMCPMC10254167
OpenAlexW4378717304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.